Sangamo Therapeutics, Inc. (0R1D.L)
USD 2.62
(-3.68%)
USD 2.62
(-3.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 228.68 Million USD | -14.16% |
| 2022 | 312.58 Million USD | 6.31% |
| 2021 | 294.03 Million USD | 18.69% |
| 2020 | 247.74 Million USD | 19.33% |
| 2019 | 207.6 Million USD | 28.47% |
| 2018 | 161.6 Million USD | 73.9% |
| 2017 | 92.92 Million USD | 1.07% |
| 2016 | 91.94 Million USD | 6.43% |
| 2015 | 86.39 Million USD | 19.3% |
| 2014 | 72.42 Million USD | 42.62% |
| 2013 | 50.77 Million USD | 15.79% |
| 2012 | 43.85 Million USD | -4.96% |
| 2011 | 46.14 Million USD | 0.87% |
| 2010 | 45.74 Million USD | 9.98% |
| 2009 | 41.58 Million USD | 0.07% |
| 2008 | 41.56 Million USD | 22.71% |
| 2007 | 33.86 Million USD | 18.37% |
| 2006 | 28.61 Million USD | 76.28% |
| 2005 | 16.23 Million USD | 1.67% |
| 2004 | 15.96 Million USD | 11.27% |
| 2003 | 14.34 Million USD | -59.63% |
| 2002 | 35.53 Million USD | 75.37% |
| 2001 | 20.26 Million USD | -4.18% |
| 2000 | 21.14 Million USD | 211.0% |
| 1999 | 6.8 Million USD | 23.73% |
| 1998 | 5.49 Million USD | 120.1% |
| 1997 | 2.49 Million USD | 162.84% |
| 1996 | 950 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 31.82 Million USD | -26.56% |
| 2024 Q1 | 43.33 Million USD | -29.45% |
| 2023 FY | 268.33 Million USD | -14.16% |
| 2023 Q2 | 79.06 Million USD | -2.82% |
| 2023 Q3 | 71 Million USD | -10.19% |
| 2023 Q4 | 61.42 Million USD | -13.5% |
| 2023 Q1 | 81.35 Million USD | -1.54% |
| 2022 Q3 | 81.35 Million USD | 8.31% |
| 2022 FY | 312.58 Million USD | 6.31% |
| 2022 Q1 | 73.49 Million USD | 8.26% |
| 2022 Q2 | 75.11 Million USD | 2.2% |
| 2022 Q4 | 82.62 Million USD | 1.56% |
| 2021 Q2 | 76.57 Million USD | 5.5% |
| 2021 Q1 | 72.58 Million USD | 4.84% |
| 2021 Q4 | 67.88 Million USD | -11.84% |
| 2021 Q3 | 76.99 Million USD | 0.56% |
| 2021 FY | 294.03 Million USD | 18.69% |
| 2020 Q2 | 59.45 Million USD | 3.22% |
| 2020 Q1 | 57.59 Million USD | 7.9% |
| 2020 Q4 | 69.23 Million USD | 12.64% |
| 2020 Q3 | 61.46 Million USD | 3.39% |
| 2020 FY | 247.74 Million USD | 19.33% |
| 2019 Q2 | 51.05 Million USD | -1.76% |
| 2019 Q4 | 53.38 Million USD | 4.25% |
| 2019 Q3 | 51.2 Million USD | 0.3% |
| 2019 FY | 207.6 Million USD | 28.47% |
| 2019 Q1 | 51.96 Million USD | 9.16% |
| 2018 Q2 | 40.55 Million USD | 20.58% |
| 2018 Q4 | 47.6 Million USD | 19.61% |
| 2018 FY | 161.6 Million USD | 73.9% |
| 2018 Q1 | 33.63 Million USD | 25.3% |
| 2018 Q3 | 39.8 Million USD | -1.86% |
| 2017 Q1 | 20.21 Million USD | 7.81% |
| 2017 Q2 | 21.02 Million USD | 3.98% |
| 2017 Q3 | 24.84 Million USD | 18.2% |
| 2017 Q4 | 26.84 Million USD | 8.03% |
| 2017 FY | 92.92 Million USD | 1.07% |
| 2016 Q3 | 22.02 Million USD | -27.88% |
| 2016 Q1 | 20.62 Million USD | -16.82% |
| 2016 FY | 91.94 Million USD | 6.43% |
| 2016 Q2 | 30.54 Million USD | 48.11% |
| 2016 Q4 | 18.75 Million USD | -14.88% |
| 2015 Q1 | 19.71 Million USD | 2.02% |
| 2015 Q2 | 20.63 Million USD | 4.68% |
| 2015 FY | 86.39 Million USD | 19.3% |
| 2015 Q3 | 21.25 Million USD | 3.0% |
| 2015 Q4 | 24.79 Million USD | 16.66% |
| 2014 Q2 | 17.4 Million USD | 11.0% |
| 2014 FY | 72.42 Million USD | 42.62% |
| 2014 Q3 | 20.02 Million USD | 15.05% |
| 2014 Q4 | 19.32 Million USD | -3.5% |
| 2014 Q1 | 15.67 Million USD | 4.63% |
| 2013 Q1 | 11.52 Million USD | -6.28% |
| 2013 Q3 | 11.86 Million USD | -4.32% |
| 2013 Q4 | 14.98 Million USD | 26.27% |
| 2013 FY | 50.77 Million USD | 15.79% |
| 2013 Q2 | 12.4 Million USD | 7.58% |
| 2012 Q1 | 10.52 Million USD | -5.29% |
| 2012 Q2 | 10.31 Million USD | -1.97% |
| 2012 Q3 | 10.7 Million USD | 3.79% |
| 2012 Q4 | 12.3 Million USD | 14.86% |
| 2012 FY | 43.85 Million USD | -4.96% |
| 2011 Q1 | 11.8 Million USD | -9.41% |
| 2011 Q2 | 11.79 Million USD | -0.05% |
| 2011 Q3 | 11.43 Million USD | -3.09% |
| 2011 Q4 | 11.11 Million USD | -2.78% |
| 2011 FY | 46.14 Million USD | 0.87% |
| 2010 Q4 | 13.02 Million USD | 11.74% |
| 2010 Q1 | 10.65 Million USD | -15.84% |
| 2010 FY | 45.74 Million USD | 9.98% |
| 2010 Q2 | 10.4 Million USD | -2.32% |
| 2010 Q3 | 11.65 Million USD | 12.05% |
| 2009 Q4 | 12.65 Million USD | 42.73% |
| 2009 Q2 | 9.88 Million USD | -2.93% |
| 2009 Q1 | 10.18 Million USD | 12.72% |
| 2009 Q3 | 8.86 Million USD | -10.29% |
| 2009 FY | 41.58 Million USD | 0.07% |
| 2008 Q2 | 10.83 Million USD | -6.41% |
| 2008 FY | 41.56 Million USD | 22.71% |
| 2008 Q4 | 9.03 Million USD | -10.8% |
| 2008 Q3 | 10.12 Million USD | -6.5% |
| 2008 Q1 | 11.57 Million USD | 11.56% |
| 2007 Q3 | 7.64 Million USD | -9.24% |
| 2007 Q2 | 8.42 Million USD | 13.37% |
| 2007 Q1 | 7.42 Million USD | -38.09% |
| 2007 Q4 | 10.37 Million USD | 35.71% |
| 2007 FY | 33.86 Million USD | 18.37% |
| 2006 FY | 28.61 Million USD | 76.28% |
| 2006 Q3 | 5.42 Million USD | -7.3% |
| 2006 Q2 | 5.84 Million USD | 9.45% |
| 2006 Q1 | 5.34 Million USD | 23.79% |
| 2006 Q4 | 11.99 Million USD | 121.3% |
| 2005 Q3 | 4.2 Million USD | 8.52% |
| 2005 Q2 | 3.87 Million USD | 0.99% |
| 2005 Q1 | 3.83 Million USD | 6.59% |
| 2005 FY | 16.23 Million USD | 1.67% |
| 2005 Q4 | 4.31 Million USD | 2.69% |
| 2004 FY | 15.96 Million USD | 11.27% |
| 2004 Q1 | 3.99 Million USD | 31.6% |
| 2004 Q2 | -3.26 Million USD | -181.83% |
| 2004 Q3 | 4.84 Million USD | 248.45% |
| 2004 Q4 | 3.59 Million USD | -25.75% |
| 2003 FY | 14.34 Million USD | -59.63% |
| 2003 Q1 | 3.62 Million USD | 3.52% |
| 2003 Q4 | 3.03 Million USD | -12.7% |
| 2003 Q3 | 3.47 Million USD | -17.72% |
| 2003 Q2 | 4.22 Million USD | 16.54% |
| 2002 Q4 | 3.49 Million USD | -84.4% |
| 2002 FY | 35.53 Million USD | 75.37% |
| 2002 Q3 | 22.43 Million USD | 416.53% |
| 2002 Q2 | 4.34 Million USD | -17.46% |
| 2002 Q1 | 5.26 Million USD | -14.27% |
| 2001 Q1 | 3.65 Million USD | -63.09% |
| 2001 FY | 20.26 Million USD | -4.18% |
| 2001 Q4 | 6.13 Million USD | 4.62% |
| 2001 Q3 | 5.86 Million USD | 27.46% |
| 2001 Q2 | 4.6 Million USD | 25.87% |
| 2000 Q2 | 3.54 Million USD | -20.82% |
| 2000 Q1 | 4.48 Million USD | 0.0% |
| 2000 FY | 21.14 Million USD | 211.0% |
| 2000 Q4 | 9.9 Million USD | 145.33% |
| 2000 Q3 | 4.03 Million USD | 13.81% |
| 1999 FY | 6.8 Million USD | 23.73% |
| 1998 FY | 5.49 Million USD | 120.1% |
| 1997 FY | 2.49 Million USD | 162.84% |
| 1996 FY | 950 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 7.531% |
| Dynavax Technologies Corporation | 219.14 Million USD | -4.351% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 56.772% |
| Perrigo Company plc | 1.52 Billion USD | 85.039% |
| Illumina, Inc. | 3.81 Billion USD | 94.003% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.77% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 49.294% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.437% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 88.861% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -89.529% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.877% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -411.966% |
| Waters Corporation | 943.51 Million USD | 75.763% |
| Biogen Inc. | 5.2 Billion USD | 95.606% |
| Evolus, Inc. | 189.75 Million USD | -20.511% |
| Adicet Bio, Inc. | 152.03 Million USD | -50.41% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -60.519% |
| bluebird bio, Inc. | 240.23 Million USD | 4.809% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 15.895% |
| FibroGen, Inc. | 398.11 Million USD | 42.559% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 89.188% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1544.04% |
| Homology Medicines, Inc. | 9.87 Million USD | -2215.747% |
| Geron Corporation | 70.44 Million USD | -224.64% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 87.296% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 46.526% |
| Myriad Genetics, Inc. | 600.1 Million USD | 61.893% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -126.804% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 58.54% |
| Zoetis Inc. | 2.76 Billion USD | 91.729% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -371.486% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 79.008% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 86.905% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.211% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -484.068% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 70.667% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 17.053% |
| Verastem, Inc. | 92.08 Million USD | -148.338% |
| Nektar Therapeutics | 190.9 Million USD | -19.789% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 51.994% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1783.535% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 83.195% |
| OPKO Health, Inc. | 574.68 Million USD | 60.208% |
| Exelixis, Inc. | 1.58 Billion USD | 85.588% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 85.676% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 37.962% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -310.144% |
| uniQure N.V. | 285.08 Million USD | 19.786% |
| Imunon, Inc. | 21.03 Million USD | -987.377% |
| Blueprint Medicines Corporation | 722.86 Million USD | 68.365% |
| Insmed Incorporated | 949.26 Million USD | 75.91% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 23.6% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 44.061% |
| TG Therapeutics, Inc. | 198.47 Million USD | -15.219% |
| Incyte Corporation | 1.19 Billion USD | 80.791% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 78.096% |